Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
December 6, 2016
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
Type:
Grant
Filed:
July 5, 2016
Date of Patent:
December 6, 2016
Assignee:
Yeda Research and Development Co. Ltd
Inventors:
Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
Abstract: Embodiments described herein relate to methods, devices, and computer systems thereof for the derivation of T CAR libraries (Universal Subject or Individual Subject) for personalized treatment of disease in a subject. In certain embodiments, differential screening of normal and diseased tissue expression data is utilized to determine disease-specific antigens and thereby generate T CAR cells reactive to such antigens to form a disease-specific library. In certain embodiments, determination of the most effective T CAR clones from the disease-specific library is based on the subject's own disease-specific antigens. In certain embodiments, a subject is treated with a therapeutically effective amount of T CAR clones.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
November 22, 2016
Assignee:
Elwha LLC
Inventors:
Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
Type:
Grant
Filed:
May 6, 2014
Date of Patent:
November 15, 2016
Assignee:
MedImmune Limited
Inventors:
Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Steward, Kathleen Ann Mulgrew
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type:
Grant
Filed:
April 9, 2014
Date of Patent:
November 15, 2016
Assignees:
Ono Pharmaceutical Co., Ltd., E.R. Squibb & Sons, L.L.C.
Inventors:
Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type:
Grant
Filed:
May 6, 2014
Date of Patent:
November 15, 2016
Assignees:
Ono Pharmaceutical Co., Ltd., E.R. Squibb & Sons, L.L.C.
Inventors:
Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
Abstract: The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).
Type:
Grant
Filed:
September 8, 2011
Date of Patent:
November 15, 2016
Assignee:
Baylor College of Medicine
Inventors:
Malcolm Brenner, Gianpietro Dotti, Nabil Ahmed, Claudia Rossig, Stephen M. G. Gottschalk, Zakaria Grada
Abstract: The present invention relates to bispecific molecules that are immunoreactive to an activating receptor of a companion animal immune effector cell and to B7-H3, and to the use of such bispecific molecules in the treatment of cancer in companion animals.
Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Type:
Grant
Filed:
December 30, 2013
Date of Patent:
October 4, 2016
Assignees:
Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
Inventors:
Gordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Type:
Grant
Filed:
March 10, 2014
Date of Patent:
October 4, 2016
Assignee:
AMGEN INC.
Inventors:
Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.
Type:
Grant
Filed:
October 10, 2013
Date of Patent:
September 20, 2016
Assignees:
Albert Einstein College of Medicine, Inc., Sloan-Kettering Institute for Cancer Research
Abstract: The present disclosure provides methods useful for prolonging the survival of an allograft organ in a recipient mammal. The methods include administration of an anti-CD200 antibody or a CD200-binding fragment of the antibody. The disclosure also provides biomarkers, a change in one or more of which indicates that an anti-CD200 antibody has produced a desired immunomodulatory effect in a mammal. Also featured are pharmaceutical compositions, kits, and solutions that contain at least one anti-CD200 antibody and are useful in the methods described herein.
Type:
Grant
Filed:
February 3, 2012
Date of Patent:
September 20, 2016
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Yi Wang, Susan Faas McKnight, Zhao Xue Yu, Hao Wang
Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.
Abstract: This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.
Type:
Grant
Filed:
July 1, 2012
Date of Patent:
August 30, 2016
Assignee:
COMPUGEN LTD.
Inventors:
Amir Toporik, Avi Yeshah Rosenberg, Galit Rotman, Iris Hecht, Zurit Levine
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Type:
Grant
Filed:
August 22, 2013
Date of Patent:
August 30, 2016
Assignee:
UCB Pharma S.A.
Inventors:
Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
Abstract: The function of natural killer (NK) cells is regulated by inhibitory and activating signals delivered by cell surface receptors, 1-7F9 is a fully human monoclonal antibody (mAb) directed against KIR2DL1 and K1R2DL2/3 receptors that blocks its interaction with its HLA-C ligands breaking NK cell tolerance to autologous tumor ceils. L?nalidomide has been shown to increase NK cell cytotoxicity in vitro. The combination of lenalidomide and 1-7F9 enhanced NK cell mediated cytotoxicity against U266 cells beyond that observed with each agent alone. Lenalidomide also increased the expression of NKG2D, DNAM-I and TRAIL ligands including: MICA, ULB P2, CD1 12 and DR 4 on U266 cells. In in vitro cytotoxicity assays, lenalidomide enhanced the susceptibility of myeloma cell lines to NK ceil. The NK ceil signaling pathways was also explored after lenalidomide treatment and the results show that lenalidomide may upregulate the phospho-SHIP1 (Tyr1020) and has no effect on phospho-p44/42 (ERK 1/2) (Thr202/Tyr204) in NK cells.
Abstract: This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains of LY6G6F, VSIG10, TMEM25 and LSR and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders. This invention further relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LY6G6F, VSIG10, TMEM25 or LSR molecules, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
Type:
Grant
Filed:
April 16, 2012
Date of Patent:
August 9, 2016
Assignee:
COMPUGEN LTD
Inventors:
Amir Toporik, Amit Novik, Ronen Shemesh
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Type:
Grant
Filed:
February 12, 2014
Date of Patent:
August 9, 2016
Assignee:
Bristol-Myers Squibb Company
Inventors:
Glen Eugene Mikesell, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach, Henry Shen